[Research progress on prognostic markers of chronic lymphocytic leukemia.]

[Guest guest]

Blank[Research progress on prognostic markers of chronic lymphocytic leukemia.]

J Mao, ZR Mao, and R Zhou

Zhejiang Da Xue Xue Bao Yi Xue Ban, May 1, 2010; 39(3): 250-6.

Institute of Pathology and Forensic Medicine, college of medicine, Zhejiang

University, Hangzhou 310058, China.

Chronic lymphocytic leukemia (CLL) remains the most common adult leukemia. The

recent progress on research of molecular and cellular genetics of CLL promotes

the development of the diagnosis, treatment and prognosis for CLL patients. IGVH

gene mutation status is the most important prognostic marker for CLL patients.

Zeta-chain-associated protein kinase (ZAP-70) can be used as a surrogate marker

for IGVH mutation status. CD38 is a type II transmembrane glycoprotein promoting

B cell activation and proliferation, which can improve the survival of CLL cells

and enhance their proliferation, so it also can be used as an independent

prognostic indicator for CLL. Chromosome aberrations are found in more than 80%

of CLL cases. The most frequent abnormalities are losses of chromosomal

material, with deletions in band 13q14 being the most common. The most common

gains of chromosomal material are trisomies 12q. Human leukocyte antigen G

(HLA-G) is a non-classical HLA-I gene. Increased expression of HLA-G leads to

the malignant progression of CLL, significantly shortens survival, indicating

HLA-G might serve as a prognostic marker in CLL. Toll-like receptors (TLA) are

important component of natural immunity. The combination of TLR agonists and

release chemotherapy, monoclonal antibodies and tumor vaccines would bring a

breakthrough for the treatment of CLL.

PMID: 20544986